Intravitreal Expert Group
  • Home
  • Virtual Clinics
  • Expert Views
  • How to Inject
  • Fundamentals
  • About Us
  • Live

Home / Aviceda submits Investigational New Drug application for AVD-104 for geographic atrophy

29th Mar 2023

Aviceda submits Investigational New Drug application for AVD-104 for geographic atrophy

News Research and clinical trials

Aviceda Therapeutics submitted Investigational New Drug (IND) and Fast Track Designation applications to the FDA to support the use of its lead intravitreal ocular asset, AVD-104 – a novel glycan-coated nanoparticle – for the treatment of GA secondary to AMD. Aviceda is a private biotech company focused on the development of next generation immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and alleviate chronic non-resolving inflammation.


“With only one currently approved therapy for the treatment of GA, there is still a significant unmet medical need for patients with this condition. This IND application brings us a step closer to offering a new and differentiated treatment option for disease modification of the key underlying pathobiology of AMD via the modulation of immune and complement dysfunction,” Mohamed Genead, MD, Co-Founder, CEO & President of Aviceda, said in a press release.


Aviceda had previously announced the successful completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies that demonstrated positive safety outcomes for multiple well-tolerated doses of AVD-104, including dose-range finding studies in non-human primates and rabbits, to support continued development and the initiation of the Phase 2 in the human clinical trials.


“As a retina specialist and ocular immunologist, I am excited about advancing AVD-104 into the clinical phase as we believe that this novel ocular nanoparticle-based therapy will be key in the treatment of this devastating blinding eye disease with enhanced efficacy, safety, and prolonged durability. We anticipate beginning our Phase 2 trial as soon as possible after FDA review,” David Callanan, MD, Aviceda’s Chief Medical Officer said. “This key milestone advances our technology to the clinical phase, and further validates the Company’s platform, which includes assets to be directed at neuro-inflammation/degeneration, oncology, fibrosis, and other rare immune pathologies.”

Source: https://eyewire.news/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd?c4src=article:infinite-scroll

Categories

  • AMD
  • Articles
  • COVID-19
  • DR and DME
  • Intravitreal injections
  • Latest contents
  • Meetings and congresses
  • News
  • Other pathologies
  • Research and clinical trials
  • Retinal imaging
  • ROP
  • RVO
  • Videos

Ethnographic study investigates the impact of geographic atrophy on patients’ life

18 April 2019

In geographic atrophy (GA), the atrophic process typica

LEARN MORE

First treatment for Geographic Atrophy (GA) approved by FDA

16 March 2023

On February 17, the FDA approv

LEARN MORE

Regenerative medicine for geographic atrophy

7 November 2019

Lucia Lee Ferraro presents a study on regenerative ther

LEARN MORE
IVEG_Logo
  • Home
  • Virtual Clinics
  • Expert Views
  • How to Inject
  • Fundamentals
  • About Us

Sign up to newsletter

Enter a valid email!

Check the boxes below to proceed with newsletter signup!

You are already in our database, update your data!

If you don't want to receive further communications, you can remove the subscription HERE

Designed and created by Etcetera Communication | privacy policy | cookie policy